Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ANO1 | Q5XXA6 | 4/20 | 0.42 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.41 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24297242 | 0.80 | KDM4E (0.40) | ALDH1A1KDM4EGLAMAPT | |
| SCHEMBL859781 | 0.79 | MAOB (0.54) | ALDH1A1KDM4EGLA | |
| SCHEMBL905177 | 0.79 | ANO1 (0.60) | CA1CA2ANO1SHMT1SHMT2 | |
| SCHEMBL24297009 | 0.78 | ALDH1A1 (0.42) | ALDH1A1KDM4EGLAMAPT | |
| SCHEMBL3252739 | 0.77 | GABRA1 (0.45) | ALDH1A1KDM4EGLAMAPTMAPK1 | |
| SCHEMBL20233513 | 0.77 | ELANE (0.46) | ALDH1A1KDM4EGLAMAPK1LMNA | |
| SCHEMBL26257146 | 0.76 | HDAC6 (0.44) | CA1CA2ALDH1A1KDM4EGLA | |
| SCHEMBL16143078 | 0.75 | EGFR (0.57) | CA1CA2ANO1SHMT1SHMT2 | |
| SCHEMBL11627168 | 0.75 | CA1 (0.54) | CA1CA2ANO1SHMT1SHMT2 | |
| SCHEMBL20382971 | 0.75 | CA1 (0.54) | CA1CA2ANO1SHMT1SHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287138-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGNERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287138-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | TGM2, QPCT, TGM3 | CA1 949/4885CA2 1524/4885ANO1 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.